TY - JOUR
T1 - Referral rates and barriers to lung transplantation based on pulmonary function criteria in interstitial lung diseases
T2 - a retrospective cohort study
AU - Deri, Ofir
AU - Ovadia, David
AU - Huszti, Ella
AU - Peled, Michael
AU - Saute, Milton
AU - Hod, Tammy
AU - Onn, Amir
AU - Seluk, Lior
AU - Furie, Nadav
AU - Shafran, Inbal
AU - Mass, Ronen
AU - Chatterji, Sumit
AU - Levy, Liran
N1 - Publisher Copyright:
© The Author(s), 2024.
PY - 2024/1/1
Y1 - 2024/1/1
N2 - Background: Interstitial lung diseases (ILD) unresponsive to medical therapy often require lung transplantation (LTx), which prolongs quality of life and survival. Ideal timing for referral for LTx remains challenging, with late referral associated with significant morbidity and mortality. Among other criteria, patients with ILD should be considered for LTx if forced vital capacity (FVC) is less than 80% or diffusion capacity for carbon monoxide (DLCO) is less than 40%. However, data on referral rates are lacking. Objectives: To evaluate referral rates for LTx based on pulmonary function tests (PFTs) and identify barriers associated with non-referral. Design: A single-center retrospective cohort study. Methods: The study consisted of ILD patients who performed PFT between 2014 and 2020. Patients with FVC < 80% or a DLCO < 40% were included in the study. Patients with absolute contraindications to LTx were excluded. Referral rates were computed, and a comparison was made between referred and non-referred subjects. Results: Out of 114 ILD patients meeting criteria for referral to LTx, 35 were referred (30.7%), and 7 proceeded to undergo LTx. Median time from PFT to referral for assessment was 255 days [interquartile range (IQR) 35–1077]. Median time from referral to LTx was 89 days (IQR 59–143). Referred patients were younger (p = 0.003), had lower FVC (p < 0.001), DLCO (p < 0.001), and a higher rate of pulmonary hypertension (p = 0.04). Relatively better PFT, and older age, were significantly associated with non-referral of patients. Conclusion: There is under-referral of ILD patients who are eligible for LTx, which is associated with severe disease and missed opportunities for LTx. Further research is required to validate these findings.
AB - Background: Interstitial lung diseases (ILD) unresponsive to medical therapy often require lung transplantation (LTx), which prolongs quality of life and survival. Ideal timing for referral for LTx remains challenging, with late referral associated with significant morbidity and mortality. Among other criteria, patients with ILD should be considered for LTx if forced vital capacity (FVC) is less than 80% or diffusion capacity for carbon monoxide (DLCO) is less than 40%. However, data on referral rates are lacking. Objectives: To evaluate referral rates for LTx based on pulmonary function tests (PFTs) and identify barriers associated with non-referral. Design: A single-center retrospective cohort study. Methods: The study consisted of ILD patients who performed PFT between 2014 and 2020. Patients with FVC < 80% or a DLCO < 40% were included in the study. Patients with absolute contraindications to LTx were excluded. Referral rates were computed, and a comparison was made between referred and non-referred subjects. Results: Out of 114 ILD patients meeting criteria for referral to LTx, 35 were referred (30.7%), and 7 proceeded to undergo LTx. Median time from PFT to referral for assessment was 255 days [interquartile range (IQR) 35–1077]. Median time from referral to LTx was 89 days (IQR 59–143). Referred patients were younger (p = 0.003), had lower FVC (p < 0.001), DLCO (p < 0.001), and a higher rate of pulmonary hypertension (p = 0.04). Relatively better PFT, and older age, were significantly associated with non-referral of patients. Conclusion: There is under-referral of ILD patients who are eligible for LTx, which is associated with severe disease and missed opportunities for LTx. Further research is required to validate these findings.
KW - interstitial lung disease
KW - lung transplantation
KW - pulmonary function tests
UR - http://www.scopus.com/inward/record.url?scp=85181741845&partnerID=8YFLogxK
U2 - 10.1177/17534666231221750
DO - 10.1177/17534666231221750
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 38179653
AN - SCOPUS:85181741845
SN - 1753-4658
VL - 18
JO - Therapeutic Advances in Respiratory Disease
JF - Therapeutic Advances in Respiratory Disease
ER -